Skip to main content

Table 2 Comorbidities of patients hospitalized who underwent a mechanical mitral valve replacement in Spain from 2001 to 2015 according to type 2 diabetes status

From: Impact of type 2 diabetes mellitus in the utilization and in-hospital outcomes of surgical mitral valve replacement in Spain (2001–2015)

 

T2DM

2001–2005

2006–2010

2011–2015

Total

Trend

Mitral stenosis, n (%)*

Yes

208 (12.68)

220 (10.94)

212 (10.09)

640 (11.12)

0.041

No

1212 (11.19)

999 (10.12)

768 (8.13)

2979 (9.88)

< 0.001

Rheumatic mitral insufficiency, n (%)*

Yes

72 (4.39)

70 (3.48)

83 (3.95)

225 (3.91)

0.368

No

428 (3.95)

418 (4.24)

475 (5.03)

1321 (4.38)

0.001

Mitral stenosis with insufficiency, n (%)*

Yes

306 (18.66)

352 (17.5)

269 (12.8)

927 (16.11)

< 0.001

No

1975 (18.23)

1663 (16.85)

1308 (13.84)

4946 (16.4)

< 0.001

Chronic obstructive pulmonary disease, n (%)*

Yes

142 (8.66)

161 (8.01)

176 (8.37)

479 (8.33)

0.774

No

695 (6.41)

641 (6.5)

600 (6.35)

1936 (6.42)

0.916

Peripheral vascular disease, n (%)*

Yes

49 (2.99)

85 (4.23)

95 (4.52)

229 (3.98)

0.046

No

236 (2.18)

349 (3.54)

404 (4.28)

989 (3.28)

< 0.001

Acute renal disease, n (%)*

Yes

148 (9.02)

207 (10.29)

306 (14.56)

661 (11.49)

< 0.001

No

744 (6.87)

1023 (10.37)

1422 (15.05)

3189 (10.58)

< 0.001

Cerebrovascular disease, n (%)*

Yes

94 (5.73)

111 (5.52)

120 (5.71)

325 (5.65)

0.952

No

468 (4.32)

423 (4.29)

503 (5.32)

1394 (4.62)

< 0.001

Congestive heart failure, n (%)

Yes

351 (21.4)

429 (21.33)

510 (24.26)

1290 (22.42)

0.040

No

2177 (20.09)

2023 (20.5)

2223 (23.52)

6423 (21.3)

< 0.001

Atrial fibrillation, n (%)*

Yes

969 (59.09)

1238 (61.56)

1298 (61.75)

3505 (60.92)

0.194

No

6152 (56.78)

5822 (59)

5549 (58.72)

17,523 (58.12)

0.002

Pulmonary hypertension, n (%)*

Yes

513 (31.28)

626 (31.13)

632 (30.07)

1771 (30.78)

0.667

No

2846 (26.27)

2735 (27.72)

2648 (28.02)

8229 (27.29)

< 0.001

Coronary artery disease, n (%)*

Yes

445 (27.13)

516 (25.66)

571 (27.16)

1532 (26.63)

0.474

No

1818 (16.78)

1674 (16.97)

1788 (18.92)

5280 (17.51)

< 0.001

Obesity, n (%)*

Yes

157 (9.57)

224 (11.14)

306 (14.56)

687 (11.94)

< 0.001

No

489 (4.51)

599 (6.07)

719 (7.61)

1807 (5.99)

< 0.001

Cardiogenic shock, n (%)*

Yes

53 (3.23)

65 (3.23)

67 (3.19)

185 (3.22)

0.996

No

387 (3.57)

414 (4.2)

415 (4.39)

1216 (4.03)

0.008

Gastrointestinal hemorrhage, n (%)

Yes

6 (0.37)

7 (0.35)

3 (0.14)

16 (0.28)

0.333

No

52 (0.48)

41 (0.42)

34 (0.36)

127 (0.42)

0.417

Endocarditis, n (%)

Yes

106 (6.46)

207 (10.29)

279 (13.27)

592 (10.29)

< 0.001

No

815 (7.52)

986 (9.99)

1212 (12.83)

3013 (9.99)

< 0.001

Pneumonia, n (%)*

Yes

51 (3.11)

51 (2.54)

29 (1.38)

131 (2.28)

0.001

No

341 (3.15)

307 (3.11)

208 (2.2)

856 (2.84)

< 0.001

Renal disease, n (%)*

Yes

108 (6.59)

178 (8.85)

270 (12.84)

556 (9.66)

< 0.001

No

430 (3.97)

529 (5.36)

669 (7.08)

1628 (5.4)

< 0.001

Liver disease, n (%)*

Yes

66 (4.02)

77 (3.83)

106 (5.04)

249 (4.33)

0.124

No

260 (2.4)

330 (3.34)

430 (4.55)

1020 (3.38)

< 0.001

Cancer, n (%)

Yes

13 (0.79)

23 (1.14)

21 (1)

57 (0.99)

0.566

No

72 (0.66)

98 (0.99)

99 (1.05)

269 (0.89)

0.007

Weight loss, n (%)

Yes

8 (0.49)

6 (0.3)

13 (0.62)

27 (0.47)

0.321

No

38 (0.35)

41 (0.42)

39 (0.41)

118 (0.39)

0.699

  1. T2DM type 2 diabetes mellitus
  2. * p < 0.05 for comparisons between T2DM patients and non-T2DM patients